195 related articles for article (PubMed ID: 21487089)
21. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
22. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Miller M; Cannon CP; Murphy SA; Qin J; Ray KK; Braunwald E;
J Am Coll Cardiol; 2008 Feb; 51(7):724-30. PubMed ID: 18279736
[TBL] [Abstract][Full Text] [Related]
23. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Kang S; Liu Y; Liu XB
Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
[TBL] [Abstract][Full Text] [Related]
24. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
25. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Scirica BM; Morrow DA; Cannon CP; Ray KK; Sabatine MS; Jarolim P; Shui A; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2006 Jun; 47(11):2326-31. PubMed ID: 16750703
[TBL] [Abstract][Full Text] [Related]
26. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Cannon CP; McCabe CH; Belder R; Breen J; Braunwald E
Am J Cardiol; 2002 Apr; 89(7):860-1. PubMed ID: 11909576
[No Abstract] [Full Text] [Related]
27. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.
Iakoubova OA; Sabatine MS; Rowland CM; Tong CH; Catanese JJ; Ranade K; Simonsen KL; Kirchgessner TG; Cannon CP; Devlin JJ; Braunwald E
J Am Coll Cardiol; 2008 Jan; 51(4):449-55. PubMed ID: 18222355
[TBL] [Abstract][Full Text] [Related]
28. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
30. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989
[TBL] [Abstract][Full Text] [Related]
31. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.
Lotfi A; Schweiger MJ; Giugliano GR; Murphy SA; Cannon CP;
Am Heart J; 2008 May; 155(5):954-8. PubMed ID: 18440347
[TBL] [Abstract][Full Text] [Related]
32. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Mega JL; Morrow DA; Cannon CP; Murphy S; Cairns R; Ridker PM; Braunwald E
J Thromb Thrombolysis; 2006 Aug; 22(1):71-6. PubMed ID: 16786236
[TBL] [Abstract][Full Text] [Related]
34. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Austin PC; Mamdani MM
Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
[TBL] [Abstract][Full Text] [Related]
35. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
36. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
37. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
[TBL] [Abstract][Full Text] [Related]
38. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Miyauchi K; Daida H; Morimoto T; Hiro T; Kimura T; Nakagawa Y; Yamagishi M; Ozaki Y; Kadota K; Kimura K; Hirayama A; Kimura K; Hasegawa Y; Uchiyama S; Matsuzaki M;
Circ J; 2012; 76(4):825-32. PubMed ID: 22451449
[TBL] [Abstract][Full Text] [Related]
39. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
